Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 7/20 | 0.77 |
| ▸ | SLC22A12 | Q96S37 | 7/20 | 0.77 |
| ▸ | EYA3 | Q99504 | 6/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.77 |
| ▸ | TTR | P02766 | 4/20 | 0.77 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.77 |
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.77 |
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | PGR | P06401 | 2/20 | 0.77 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.77 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.77 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.77 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | EYA2 | O00167 | 1/20 | 0.77 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.77 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.77 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.77 |
| ▸ | USP2 | O75604 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11844336 | 0.88 | TTR (0.79) | CYP2C19SLC22A12EYA3CYP2C9TTR | |
| Benzbromarone SCHEMBL29361528 | 0.87 | SLC22A12 (1.00) | CYP2C19SLC22A12EYA3CYP2C9TTR | |
| Benzbromarone SCHEMBL19205474 | 0.87 | SLC22A12 (1.00) | CYP2C19SLC22A12EYA3CYP2C9TTR | |
| Benzbromarone SCHEMBL48993 | 0.87 | SLC22A12 (1.00) | CYP2C19SLC22A12EYA3CYP2C9TTR | |
| SCHEMBL9444916 | 0.86 | CYP2C19 (0.77) | CYP2C19SLC22A12EYA3CYP2C9TTR | |
| SCHEMBL1287632 | 0.85 | EYA3 (0.68) | CYP2C19SLC22A12EYA3CYP2C9TTR | |
| SCHEMBL1287955 | 0.85 | EYA3 (0.68) | CYP2C19SLC22A12EYA3CYP2C9TTR | |
| SCHEMBL1287675 | 0.85 | EYA3 (0.79) | CYP2C19SLC22A12EYA3CYP2C9TTR | |
| SCHEMBL18058593 | 0.85 | CYP2C19 (0.81) | CYP2C19SLC22A12EYA3CYP2C9TTR | |
| SCHEMBL1288110 | 0.84 | CYP2C19 (0.75) | CYP2C19SLC22A12EYA3CYP2C9TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005750-B2 | Developing potent urate transporter inhibitors: compounds designed for their uricosuric action | J-PHARMA CO., LTD. (JP) | 2018-06-26 | — | — | US | disclosed |
| US-20130225673-A1 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | J-PHARMA CO., LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
| CN-103242272-A | Method for preparing benzbromarone | HEFEI YIGONG MEDICAL CO LTD | 2013-08-14 | — | — | CN | disclosed |
| WO-2012048058-A2 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | J-PHARMA CO., LTD. (JP) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005750-B2 | Developing potent urate transporter inhibitors: compounds designed for their uricosuric action | SLCO2B1, SLCO2A1, SLC10A6 | CYP2C19 269/4885SLC22A12 19/4885EYA3 4828/4885 |
| US-20130225673-A1 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | SLCO2B1, SLCO2A1, SLC10A6 | CYP2C19 269/4885SLC22A12 19/4885EYA3 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.